Johnson & Johnson reported Phase 3 data showing Tecvayli reduced the risk of disease progression or death versus standard regimens in relapsed multiple myeloma. Trial monitors detected an early survival advantage that prompted unblinding; J&J said Tecvayli reduced the hazard of progression or death by 71% in the primary analysis and cut mortality risk in secondary measures. J&J plans regulatory discussions with the FDA and to present the results at a medical meeting. Tecvayli is a dual‑targeting bispecific antibody designed to engage tumor cells and immune effectors simultaneously; bispecifics bind two distinct targets to redirect immune activity toward cancer cells.